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Purpose: Ulcerative colitis (UC) may cause many patients to miss out on important personal 
and professional opportunities. We therefore conducted a survey (UC-LIFE) to assess patients’ 
perceptions of the impact of UC on social and professional lives.
Patients and methods: Consecutive unselected UC patients aged $18 years were recruited 
from 38 outpatient clinics in Spain. Patients completed the survey at home, returning it by post. 
The survey comprised 44 multiple-choice questions, including questions about the impact of 
UC on social, personal, professional, and academic activities.
Results: Of 585 patients invited, 436 (75%) returned the survey (mean age 46 years; 47% 
women). High proportions of patients considered their disease “sometimes”, “frequently” or 
“mostly/always” influenced leisure activities (65.1%), recreational or professional activities 
(57.6%), or relationships with relatives or friends (9.9%). Patients also reported that UC influ-
enced their decision to have children (17.2%), or their ability to take care of children (40.7%); 
these percentages were higher in women and in younger patients. Overall, 47.0% of patients 
declared that UC influenced the kind of job they performed, 20.3% had rejected a job due to UC, 
14.7% had lost a job due to UC, and 19.4% had had academic problems due to UC.
Conclusion: Beyond symptoms alone, UC imposes an enormous additional burden on patients’ 
social, professional, and family lives. This extra burden clearly needs to be addressed so that 
the ultimate goal of IBD treatment – normalization of patient quality of life – can be attained 
by as many patients as possible.
Keywords: disease burden, patient-reported outcomes, patients’ perceptions, quality of life, 
ulcerative colitis
Introduction
Ulcerative colitis (UC) is a chronic and idiopathic inflammatory bowel disease (IBD) 
affecting the mucosal layer of the colon. The degree of mucosal involvement varies 
from proctitis (only the rectum is affected) to pancolitis (the entire colon is affected). 
UC is typically diagnosed in early adulthood and clinically characterized by relaps-
ing and remitting symptoms such as diarrhea, rectal bleeding, abdominal pain, fecal 
urgency, weight loss, and fatigue; in up to one third of patients, these symptoms are 
accompanied by articular, dermatological, and/or ocular diseases.1,2 Although most UC 
patients present with a mild-to-moderate disease course, about 14%–17% of patients 
may experience an aggressive course.3 These patients may require hospital admission, 
and up to 19% of patients with pancolitis will need colectomy, typically during the 
first 2 years after diagnosis.4 Thus, although UC does not reduce life expectancy, it is 
a markedly disabling disease for a considerable number of patients.5
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UC presents two peaks of incidence: the main one at age 
30–40 years, and another one at about 60 years.1 Younger 
patients seem to present with a worse disease course than 
patients with disease onset after age 60 years.6 As UC fre-
quently begins during a stage of life when people develop a 
professional career and start a family, and together with its 
hallmark symptoms, chronicity, and relapsing nature, the 
condition has a substantial impact on patients’ lives, in many 
cases, important personal and professional opportunities may 
be lost for patients.7–13
Globally, the incidence and prevalence of UC have 
been increasing over time, as have costs associated with 
the disease.14 In Europe, the annual direct and indirect costs 
related to UC are estimated to be as high as €12.5–29.1 billion. 
More than half of this figure is attributable to the indirect 
cost of absence from paid work, which includes costs 
associated with sick leave, early retirement, and reduced 
employment.15
Because the burden of UC surpasses clinical symptoms 
alone, we considered it interesting to collect information 
directly from patients through a cross-sectional survey 
(UC-LIFE) about their perception of how UC affects various 
aspects of their everyday lives. The survey characteristics 
and several outcomes have been published previously.16–18 
Herein, we present insights from the UC-LIFE survey about 
the impact of UC on the social and professional lives of 
Spanish patients followed in outpatient clinics.
Patients and methods
ethics approval
The study was reviewed and approved by the Clinical 
Investigation Ethics Committee of the Parc Taulí Hospital, 
Barcelona, Spain. The survey documentation included 
printed instructions and information for patients about the 
anonymous nature of the survey and aggregated data process-
ing which ensured that patient identification was not possible. 
Given that no identifiable information was collected, and as 
accepted by the Clinical Investigation Ethics Committee, no 
signed informed consent was requested, the voluntary return 
of completed questionnaires was taken as implied consent to 
participate in the study.
A detailed description of the UC-LIFE survey, subjects, 
and procedures has been published previously.16–18 A brief 
summary of study methodology, participants, and procedures 
is provided in the following section.
Unselected patients aged $18 years with UC who were 
attending one of 38 representative hospital gastroenterology 
clinics throughout Spain were recruited consecutively for 
the study and handed the survey.
At-home completion of the survey was voluntary and 
anonymous, with no collection of clinical data; invited 
patients received no reminders to complete the survey.
The UC-LIFE survey consisted of 44 multiple-choice 
questions regarding details about patient demographics; 
perceptions about the burden associated with UC symptoms 
and severity; the emotional burden of the disease in terms of 
daily life and other aspects described previously.16–18 Specifi-
cally, the survey included questions about the impact of UC 
on social, personal, professional, and academic activities of 
patients, and about the influence of UC on childcare. These 
questions were formulated with wording based on physician 
and patient recommendations. Several questions included a 
Likert scale ranging from “never” to “mostly/always”, while 
others were answered as “yes” or “no”. The full questionnaire 
is available as supplemental content to the main publication: 
http://links.lww.com/EJGH/A110.16
Due to the exploratory and descriptive nature of the survey, 
there was no formal statistical hypothesis or pre-determined 
sample size. Mean and SDs were used to describe quantitative 
variables or, if data were not distributed normally, median and 
interquartile range (IQR) were used. Frequencies or percent-
ages were used for nominal or ordinal variables. Proportional 
data (eg, gender, age, disease duration, burden of symptoms 
during the previous year) were compared using the Chi-
squared or Fisher exact tests. Multiple subgroup comparisons 
were performed using the least significant differences test. 
Statistical significance was considered for P-values #0.05. 
Statistical analyses were conducted using SPSS software 
(version 18.0.0; SPSS Inc., Chicago, IL, USA).
Results
Demographic data
Thirty-nine physicians handed out the survey to 585 UC 
patients, and 436 patients returned the questionnaire (response 
rate 74.5%). Due to the anonymous nature of the survey, the 
profile of non-responding patients is unknown. Responders 
had a mean age of 46.2 (SD 13.6) years, 52.8% were men, 
and the median duration of UC was 8 years (IQR 4–15). 
Sixty-nine percent of patients were married or had a partner, 
and 52.7% were active workers. When asked about perceived 
symptom burden during the previous year, 47.1% of patients 
reported “symptoms controlled”, and 28.0% and 24.9%, 
respectively, reported “symptoms not impairing everyday 
life” or “symptoms impairing everyday life”.
impact of Uc on social and family life
Figure 1 depicts the responses of patients to statements about 
how they perceived the impact of UC on their social lives. 




Uc: impact on social and professional life
A high proportion of patients considered their disease “some-
times”, “frequently” or “mostly/always” influenced leisure 
activities (65.1% of patients), recreational or professional 
activities (57.6%), or relationships with relatives or friends 
(9.9%). For several statements related to leisure activities, 
the percentage of patients who responded “frequently” or 
“mostly/always” was significantly higher in patients who per-
ceived more severe UC-related symptoms (Table 1). None-
theless, substantial proportions of patients who described 
their UC-related symptoms as “controlled” or “present but 
not impairing everyday life” still responded “frequently” or 
“mostly/always” to questions about leisure activities: for 
example, 32.0% of patients with symptoms “controlled” and 
52.3% of those with symptoms “present but not impairing 
everyday life” responded “frequently” or “mostly/always” to 
the statement “I take into account whether a WC is close when 
I plan my leisure activities”. The frequencies of responses 
were similar by tertiles of age and disease duration (data not 
shown), but frequencies of a “frequently” or “mostly/always” 
response to several statements were slightly higher in women 
than in men (Figure 2).
Patients were asked about the impact of UC on their 
decision to have children and their ability to take care of 
children (Table 2). Excluding patients who responded that 
these questions did not apply to them (n=126 and n=147, 
respectively), 48 of 278 patients (17.2% overall: 7.4% of men; 
28.4% of women) reported that UC had influenced their deci-
sion to have children, and 104 of 255 patients (40.7% overall: 
30.0% of men; 52.0% of women) agreed that UC influenced 
their ability to take care of children. The percentages of 
Table 1 Proportiona of patients who responded “frequently” or “mostly/always” to questions about their social lives









i take into account whether a Wc is close when i plan my 
leisure activities
211 (51.3) 57 (32.0) 56 (52.3) 80 (83.3) ,0.001
My illness influences the kind of activities I do in my leisure time 109 (27.9) 21 (12.6) 24 (23.1) 58 (61.7) ,0.001
i have stopped participating in recreational or professional 
activities due to my illness
80 (20.6) 14 (8.4) 17 (16.4) 46 (49.4) ,0.001
My illness has influenced the kind of friendships I have 15 (3.8) 4 (2.4) 3 (2.8) 6 (6.4) 0.213
i have lost touch with friends due to my illness 5 (1.3) 2 (1.2) 1 (0.9) 2 (2.1) 0.746
i have separated from a partner due to my illness 3 (0.8) 1 (0.6) 0 (0.0) 2 (2.2) 0.502
Notes: aData shown are number (%) of patients. Because some patients did not respond to the perceived symptomatic burden of Uc question, the sum of the different 
options does not always match the total number.
Abbreviations: ns, not significant; UC, ulcerative colitis; WC, water closet.
Figure 1 Patients’ responses to statements about the impact of ulcerative colitis on their social lives.
Note: numbers within the figure are percentages. 
Abbreviation: Wc, water closet.





patients reporting this negative impact of UC were statisti-
cally significantly greater in women than in men, in younger 
patients (aged #38 years), and in patients who reported that 
symptoms impaired everyday life (Table 2).
impact of Uc on professional and 
academic life
Patients were asked to respond “yes/no” to five different 
statements about their professional and academic lives. 
Between 13% and 20% of patients responded that ques-
tions about working life did not apply to them; one third 
of patients considered that questions about academic life 
did not apply to them. Excluding these patients, an overall 
negative impact of UC on professional and academic factors 
was described, as exemplified by 47.0% of patients declaring 
that UC influenced the kind of job they performed, 63.7% 
reporting sick leave due to UC, and 19.4% considering that 
they had had problems in pursuing their studies due to UC 
(Table 3). Percentages were similar in men and women 
but were greater in patients who had reported symptoms 
during the previous year, especially if symptoms had 
impaired everyday life (Figure 3). Patients with longer 
disease duration described episodes of sick leave more 
frequently (52.5%, 73.5%, and 68.4% of patients with UC 
duration ,5, 5–12, and .12 years, respectively; P=0.005), 
with no influence of disease duration on the other state-
ments. The percentages of patients who reported having lost 
a job or having had problems in pursuing their studies due 
to UC were significantly greater in the younger age group 
(aged #38 years; Figure 4).
Figure 2 Percentages of men and women who responded “frequently” or “mostly/always” to statements about the impact of ulcerative colitis on their social lives.
Abbreviations: ns, not significant; WC, water closet.
Table 2 Proportion (%) of patients who responded “yes” to 
questions about childcarea




If you have 
children, does UC 
influence your 
ability to take 
care of them?





#38 years 28.4 48.9
.38–52 years 18.6 47.2
.52 years 0.3 26.7
Uc duration 0.860 0.190
0–5 years 18.9 34.8
.5–12 years 20.8 48.1
.12 years 17.6 37.0
Perceived symptom burden 0.009 ,0.001
controlled 15.2 22.4
not impairing everyday life 11.9 36.6
impairing everyday life 30.7 65.2
Notes: Data shown are percentages of patients. aexcluding patients who responded 
that these questions did not apply to them (n=126 and n=147, respectively).
Abbreviation: Uc, ulcerative colitis.




Uc: impact on social and professional life
Discussion
The principal findings of this large, cross-sectional survey are 
the significant, patient-perceived burdens of UC on social and 
family life, and on professional and academic life. These find-
ings are of considerable relevance for several reasons: first, 
these kinds of findings are not frequently reported from large 
populations, and even less frequently directly from patients, 
with no physician intervention or interpretation. Second, we 
provided a comprehensive description of the social and pro-
fessional impact of the disease and described a link to disease 
activity as perceived by the patient. Finally, these specific 
impacts are evident even in patients who reported that their 
symptoms were “controlled”, which is something that merits 
special attention. High proportions of patients reported that 
UC markedly influenced leisure activities and relationships 
with relatives or friends. This applied even in patients who 
reported that symptoms were “controlled” or “not impairing 
daily life”. Substantial proportions of patients also reported 
that UC had influenced their decision to have children, or 
their ability to look after children. These proportions were 
significantly greater in younger patients, and patients with a 
high perceived symptom burden. Regarding professional and 
academic life, almost half of patients reported that UC influ-
enced the job they performed, almost two thirds documented 
sick leave due to UC, and almost one fifth reported difficulties 
in pursuing their studies because of UC. A significantly 
Table 3 Proportiona of patients who responded “yes” to questions about professional or academic factorsb
Have you ever been in any of the following situations? Total Men Women P-value
i have had sick leave due to my Uc 214 (63.7) 121 (65.4) 93 (61.6) 0.469
My illness has influenced the kind of job I perform 162 (47.0) 88 (47.8) 74 (47.0) 0.729
i have rejected a job due to my Uc 60 (20.3) 26 (16.7) 34 (24.3) 0.104
i have had problems with my studies due to my Uc 44 (19.4) 16 (14.7) 28 (23.7) 0.319
i have lost a job due to my Uc 43 (14.7) 26 (16.6) 17 (12.6) 0.340
i have had to leave my studies due to my Uc 12 (5.5) 4 (3.8) 8 (6.9) 0.319
Notes: aData shown are number (%) of patients. bexcluding patients who responded that these questions did not apply to them.
Abbreviation: Uc, ulcerative colitis.
Figure 3 Percentages of patients who responded “yes” to statements about the impact of ulcerative colitis on professional and academic life (stratified by perception of 
symptomatic burden).
Abbreviations: ns, not significant; UC, ulcerative colitis.





greater proportion of younger patients compared to older 
patients had lost a job because of UC or had experienced 
study problems due to UC.
Particular strengths of the current survey are its ability to 
glean real-world evidence from the patient perspective and 
obtain broader knowledge of the overall impact of UC on 
patient quality of life (QoL). This is particularly pertinent 
given the ever-increasing focus on patient-reported outcomes 
in IBD,16,19 and the increasing recognition of often divergent 
goals of physicians and IBD patients. In fact, it has been 
described previously that the most desirable goals for patients 
are often symptom control and normalization of QoL,16,19 
goals that must be attained together with the histological 
goal of complete mucosal healing. Indeed, the continuous 
control of symptoms in UC patients has been associated 
with long-term steroid-free remission, endoscopic remission, 
and mucosal healing,20 but minimizing the impact of UC on 
patients’ social and professional life must also be taken into 
account as a patient goal. Attaining both physicians’ and 
patients’ goals might therefore be the optimal objective in 
achieving complete UC clinical control.
We have previously described that the prevalence of spe-
cific UC symptoms was substantial even among patients who 
had defined their symptoms as “controlled”,16 suggesting that 
patients could accept some degree of living with troublesome 
symptoms as “normal”. In the current work, we extended this 
finding to several effects of UC on social and professional life: 
patients who considered their symptoms to be “controlled” 
also described frequent limitations with regard to social and 
professional life. In failing to realize the full therapeutic 
potential of treatment, many patients may fail to attain the 
maximum possible QoL improvements. Even in the presence 
of endoscopic and symptomatic cure, many IBD patients do 
not attain normalization of QoL.21,22 These patients may be 
Figure 4 Percentages of patients who responded “yes” to statements about the impact of ulcerative colitis on professional and academic life (stratified by age [tertiles]).
Abbreviations: ns, not significant; UC, ulcerative colitis.




Uc: impact on social and professional life
more likely to experience problems with fatigue, anxiety, 
depression, deteriorating treatment adherence, and increased 
work disability.8,21,23 A direct consequence will likely be an 
increased overall use of health care resources.21
Our survey, in highlighting the major scale of disease 
burden posed by UC, endorses other study findings. Regard-
ing family life, for instance, the extent of misperception about 
IBD and fertility is broadly recognized. A Mediterranean-
region study reported that more than 60% of women with 
IBD were fearful that their disease and treatment might lead 
to a complicated pregnancy and fetal damage.11 An Austra-
lian study also outlined that, after a diagnosis of IBD, three 
quarters of women were worried about passing the disease 
to their offspring, about half were worried about infertility, 
and approximately one third considered not having children.12 
Other researchers corroborated that “voluntary” childless-
ness in IBD patients may result from apparently unjustified 
concerns about detrimental reproductive outcomes.13
Regarding the impact of IBD on social life and leisure 
activities, our survey found that, even in patients with symp-
toms reported as “controlled” or “not impairing daily life”, the 
disease had a marked negative influence on several aspects 
of social life: 32% and 52% of those patients, respectively, 
reported the need for a nearby WC when planning leisure 
activities; 13% and 23%, respectively, expressed that IBD 
influenced the type of activity undertaken; and 8% and 16%, 
respectively, indicated that they had stopped participating 
in recreational or professional activities because of IBD. 
These findings are in line with data from the initial UC-LIFE 
publication,16 which revealed that patients who considered 
their symptoms “controlled/nearly controlled” still experi-
enced a marked prevalence of some symptoms: diarrhea, 
urgency, rectal bleeding, flatulence, fatigue, abdominal pain, 
and joint pain. Moreover, the UC-LIFE survey showed that 
high symptom burden during the previous year (ie, “symp-
toms impairing everyday life”) had a significant influence on 
all evaluated aspects of patients’ social, personal, and pro-
fessional lives. This clearly underscores the suggestion that 
attainment of symptom control in UC patients is an essential 
first step toward true normalization of QoL.
Our survey findings of a markedly deleterious effect of 
IBD on various aspects of professional and academic life 
are clearly in agreement with data from large surveys,24 
systematic reviews,10 and other trials.8,9,25 For example, in a 
large European survey in .4,500 IBD patients, most patients 
reported that their disease had caused absence from work, and 
45% commented that IBD had a negative impact on educa-
tional performance.24 Moreover, in a study of IBD patients at 
a Dutch outpatient clinic, de Boer et al documented that 25% 
of employed patients were on sick leave, about one quarter 
were receiving a disability pension, and approximately three 
quarters had work-related difficulties such as concentration 
problems and slow work pace.8 A lack of paid employment 
was associated with worse QoL and greater rates of anxiety 
and depression.8
Another interesting finding in our survey was the major 
impact of age on work and academic performance: notably, 
among patients aged #38 years, 18% reported that UC had 
caused them to lose their job, and 24% reported that UC had 
caused study problems. Speculation suggests that such high 
rates of work loss and study impairment in young patients 
may be linked with increased rates of psychological and 
psychiatric morbidity (eg, anxiety, depression).26,27
While it is difficult to accurately quantify the holistic 
burden of UC on social and professional life, the UC-LIFE 
survey is a significant step in this direction, and its findings 
highlight the need to tackle the consequences of UC not only 
from medical, but also from social perspectives. However, 
the study has some limitations:16 data were derived from 
patient self-assessment of symptoms during the previous 
year and may therefore have been confounded by recall 
bias; and some degree of selection bias was present, since 
the survey was distributed through hospital outpatient clin-
ics, and the population did not truly reflect the overall UC 
population. Thus, study findings from these selected patient 
groups in Spain are not necessarily applicable to other geo-
graphical areas and to broader populations of UC patients. 
Nevertheless, only when efforts have been made to quantify 
the full impact of UC on QoL, including on aspects beyond 
straightforward symptom control (ie, on aspects of social, 
professional, and family lives), can attempts be made to fully 
normalize QoL in UC patients. Future studies, using objec-
tive, well-validated measures, are now warranted to more 
clearly define the impact of UC on QoL, and the effects of 
treatment and improved adherence to treatment in normal-
izing QoL in UC patients.
Conclusion
The insights from patients presented here underscore how 
UC can influence many aspects of patients’ everyday lives, 
including social and family activities and relationships, and 
freedom to enjoy leisure time and participate in professional 
and academic activities; UC can also have a major bearing on 
potentially life-changing decisions for patients, such as which 
type of employment to pursue, or whether or not to have 
children. These aspects are seldom considered or addressed in 





studies and are difficult to quantify, but impose an enormous 
extra burden on patients, well beyond UC symptoms alone. 
Such aspects of patients’ social, professional, and family lives 
clearly need to be addressed, in line with patient-centered 
approaches to UC management, so that the ultimate goal 
of IBD treatment – normalization of patient QoL – can be 
attained by as many patients as possible.
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